NASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free ABEO Stock Alerts $7.53 -0.40 (-5.04%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$7.51▼$8.1750-Day Range$6.15▼$8.6852-Week Range$2.83▼$9.01Volume245,958 shsAverage Volume324,338 shsMarket Capitalization$205.95 millionP/E RatioN/ADividend YieldN/APrice Target$38.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Abeona Therapeutics alerts: Email Address Abeona Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside404.6% Upside$38.00 Price TargetShort InterestBearish7.73% of Float Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.85Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.83) to ($1.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.73 out of 5 starsMedical Sector221st out of 918 stocksPharmaceutical Preparations Industry84th out of 405 stocks 3.5 Analyst's Opinion Consensus RatingAbeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbeona Therapeutics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.73% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Abeona Therapeutics has recently increased by 17.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAbeona Therapeutics has received a 69.10% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases ", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Abeona Therapeutics is -1.03. Previous Next 2.7 News and Social Media Coverage News SentimentAbeona Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Abeona Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 14 people have searched for ABEO on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Abeona Therapeutics are expected to grow in the coming year, from ($1.83) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 12.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About Abeona Therapeutics Stock (NASDAQ:ABEO)Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Read More ABEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABEO Stock News HeadlinesApril 16, 2024 | americanbankingnews.comAbeona Therapeutics (NASDAQ:ABEO) Upgraded to Hold at StockNews.comApril 14, 2024 | americanbankingnews.comAbeona Therapeutics Inc (NASDAQ:ABEO) Short Interest UpdateApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 1, 2024 | globenewswire.comAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 27, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn SituationMarch 19, 2024 | investorplace.comABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023March 19, 2024 | finance.yahoo.comQ4 2023 Abeona Therapeutics Inc Earnings CallMarch 19, 2024 | finance.yahoo.comAbeona Therapeutics Inc (ABEO) Reports Full Year 2023 Financial ResultsApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 18, 2024 | msn.comInventiva Phase 2 study for MASH drug meets primary endpointMarch 18, 2024 | marketwatch.comAbeona Therapeutics Shares Drop 13% After FDA Inspection of Cleveland FacilityMarch 18, 2024 | finanznachrichten.deAbeona Therapeutics Inc.: Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA InspectionsMarch 18, 2024 | msn.comAbeona Therapeutics GAAP EPS of -$2.53, revenue of $3.5MMarch 18, 2024 | globenewswire.comAbeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA InspectionsMarch 16, 2024 | finance.yahoo.comABEO Dec 2024 15.000 callMarch 10, 2024 | fool.comAbeona Therapeutics (NASDAQ: ABEO)March 10, 2024 | finance.yahoo.comSeveral Insiders Invested In Abeona Therapeutics Flagging Positive NewsMarch 5, 2024 | globenewswire.comAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 22, 2024 | benzinga.comAbeona Therapeutics Stock (NASDAQ:ABEO), Short Interest ReportFebruary 21, 2024 | benzinga.comAbeona Therapeutics Stock (NASDAQ:ABEO) Insider TradesFebruary 20, 2024 | money.usnews.comAbeona Therapeutics IncFebruary 19, 2024 | finance.yahoo.comABEO Apr 2024 7.500 callFebruary 16, 2024 | finance.yahoo.comABEO Mar 2024 10.000 callFebruary 16, 2024 | investing.comAbeona Therapeutics Inc (ABEO)February 15, 2024 | finance.yahoo.comSteven Cohen's Firm Increases Stake in Abeona Therapeutics IncFebruary 12, 2024 | finance.yahoo.comIndividual investors in Abeona Therapeutics Inc. (NASDAQ:ABEO) are its biggest bettors, and their bets paid off as stock gained 45% last weekFebruary 3, 2024 | finanznachrichten.deAbeona Therapeutics Inc.: Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)See More Headlines Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/18/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CUSIPN/A CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$38.00 High Stock Price Target$38.00 Low Stock Price Target$38.00 Potential Upside/Downside+404.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,190,000.00 Net MarginsN/A Pretax Margin-1,548.23% Return on Equity-280.58% Return on Assets-76.90% Debt Debt-to-Equity RatioN/A Current Ratio4.15 Quick Ratio4.15 Sales & Book Value Annual Sales$3.50 million Price / Sales58.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book12.55Miscellaneous Outstanding Shares27,350,000Free Float25,905,000Market Cap$205.95 million OptionableOptionable Beta1.49 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Steven H. Rouhandeh (Age 61)Exec. Chairman Dr. Timothy J. Miller (Age 46)Pres, Chief Scientific Officer & Director Mr. Jeffrey Blaine Davis (Age 55)Chief Operating Officer Mr. Carsten Thiel (Age 54)Chief Exec. Officer Mr. Stephen B. Thompson (Age 64)Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer Key CompetitorsSilverback TherapeuticsNASDAQ:SBTXG1 TherapeuticsNASDAQ:GTHXGalectin TherapeuticsNASDAQ:GALTDesign TherapeuticsNASDAQ:DSGNGeneration BioNASDAQ:GBIOView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 348,196 shares on 3/11/2024Ownership: 4.445%Vanguard Group Inc.Bought 348,196 shares on 2/15/2024Ownership: 4.445%Barclays PLCSold 201,544 shares on 2/15/2024Ownership: 0.685%Citadel Advisors LLCBought 8,600 shares on 2/15/2024Ownership: 0.000%Point72 Asset Management L.P.Sold 420,200 shares on 2/14/2024Ownership: 3.072%View All Insider TransactionsView All Institutional Transactions ABEO Stock Analysis - Frequently Asked Questions Should I buy or sell Abeona Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ABEO shares. View ABEO analyst ratings or view top-rated stocks. What is Abeona Therapeutics' stock price target for 2024? 1 equities research analysts have issued twelve-month price objectives for Abeona Therapeutics' stock. Their ABEO share price targets range from $38.00 to $38.00. On average, they expect the company's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 404.6% from the stock's current price. View analysts price targets for ABEO or view top-rated stocks among Wall Street analysts. How have ABEO shares performed in 2024? Abeona Therapeutics' stock was trading at $5.01 at the start of the year. Since then, ABEO stock has increased by 50.3% and is now trading at $7.53. View the best growth stocks for 2024 here. Are investors shorting Abeona Therapeutics? Abeona Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,990,000 shares, an increase of 17.1% from the March 15th total of 1,700,000 shares. Based on an average trading volume of 333,800 shares, the days-to-cover ratio is presently 6.0 days. Approximately 7.7% of the shares of the stock are sold short. View Abeona Therapeutics' Short Interest. When is Abeona Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ABEO earnings forecast. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc (NASDAQ:ABEO) posted its quarterly earnings data on Monday, March, 18th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.13. When did Abeona Therapeutics' stock split? Abeona Therapeutics's stock reverse split on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Abeona Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), TherapeuticsMD (TXMD), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD). How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABEO) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop 5 AI Stocks to Buy for 2024Market Moving TrendsHow Biden has already won 2024Porter & CompanyOptions trading has suddenly become more reliable.Eagle Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.